Asimakidou, Evridiki, Richard Reynolds, Anna M
Similarly, PDX experiments in this study showed that tumors with high ACTL6A expression were more sensitive to administration of BSO, a GCLC inhibitor
Stopping may lead to loss of blood sugar control and, in some cases, return of appetite or weight regain
GLP-1 Receptor Expression and Intestinal Inflammation GLP-1 receptors are expressed on intestinal immune cells, enteric neurons, and epithelial barriers, where they modulate inflammatory responses and bacterial translocation
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
